[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
Clinician's Corner
March 6, 2013

Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication

Author Affiliations
 

JAMA Clinical Evidence Synopsis Section Editor: Mary McGrae McDermott, MD, Contributing Editor. We encourage authors to submit papers for consideration as a JAMA Clinical Evidence Synopsis. Please contact Dr McDermott at mdm608@northwestern.edu

Author Affiliations: Department of Vascular Surgery, James Cook University Hospital, Middlesbrough, England (Dr Wong); National Clinical Guideline Centre, Royal College of Physicians, London, England (Dr Chong); and Department of Vascular Surgery, Freeman Hospital, Newcastle upon Tyne, England (Dr Stansby).

JAMA. 2013;309(9):926-927. doi:10.1001/jama.2013.1490
Abstract

Clinical Question Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality?

Bottom Line In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.

×